SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?


To: benwood who wrote (174609)6/22/2002 1:32:27 PM
From: JHP  Read Replies (2) | Respond to of 436258
 
<< . Earlie has very timely and topical things to say and is always worth reading, in my opinion. Neither he nor MB will be 100% perfect but you will be richer for reading what they have to say (and get numerous chuckles along the way).>>

--Ben

totally agree
both have way to many GREAT calls to single them out!


<<GSL may well have a few surprises ahead for its investors. A recent short news release provides a hint. The stock price is up on the news, but will likely subside over the next few weeks. I would be a buyer around $US1.00 to $US1.25 after the current burst of enthusiasm subsides a bit.>>
well using MB thirds, $1 ,$.50, $.10
how you doing?
and i never did,just picked some up for 12&13 cents



To: benwood who wrote (174609)6/23/2002 12:54:58 AM
From: LLCF  Respond to of 436258
 
Good advice... own DD. And thanks for digging those up... I find this illuminating and it will help me hang on longer:

<<Kinross will likely move on it sometime this year,... hopefully early in the year. I'll post when anything is noted.>>

What's with this??? Well, it reminds me of biotech when they couldn't raise a freakin dime. [like now! ROFLMAO] Kinross owns a chunk of GSL, and the stock is flying. This is VERY important because of Kinross can float some more stock, and know the GSL story you've got the spigget turned on. Contracts and deals are very important in this business just like Biotech.

DAK